Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Leonard Farber, MD and Kenneth Blank, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
Authors: Sneed PK, Stauffer PR, McDermott MW, et. al.
Source: International Journal of Radiation Oncology, Biology and Physics, 15 January 1998, Volume 40 number 2 p287
Glioblastomas are among the most aggressive of human cancers. These tumors of the brain have a median survival of approximately one year despite the best treatment. Current standard treatment of glioblastomas includes surgery, radiation and chemotherapy. One strategy that has been extensively studied at the University of California San Francisco (UCSF) is the addition of a brachytherapy boost to conventional radiotherapy. Brachytherapy involves the placement of radioactive seeds into the tumor bed at the time of surgery. This treatment allows a high dose of radiation to be given to the tumor bed but spares the surrounding brain tissue.
Another treatment method under study is hyperthermia which involves elevating tissue temperature above 41 degrees Celsius. Hyperthermia not only kills tumor cells directly but may also make cells more sensitive to radiation by inducing re-oxygenation. Several non-randomized studies which demonstrated a benefit to treating glioblastomas with hyperthermia led the Brain Tumor Research Group to conduct a randomized prospective trial which is reported in the January 15, 1998 issue of the International Journal of Radiation Oncology, Biology and Physics.
From 1990 to 1995 112 patients were enrolled on this trial. All patients received surgery and external beam radiotherapy. Patients who were eligible for a brachytherapy boost were randomized to receive 30 minutes of hyperthermia before and after the boost or no hyperthermia. Thirty-three of the 112 patients were not randomized, most commonly because of tumor progression, leaving forty patents who received hyperthermia and thirty-nine who did not. Those patients who underwent hyperthermia had significantly longer survival times and time before progression. Two year survivor rates were 31% in the hyperthermia arm versus 15% in the no hyperthermia group.
This is the first North American trial showing a benefit to hyperthermia. Further studies are warranted before a change in the standard of care of glioblastomas will include hyperthermia, but the results reported here are very encouraging.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults